Can BCR inhibitors be used to treat all CLL patients or only a subset?
Adopting new cancer treatments by continuing medical education
The importance of the collaboration of the solid and liquid tumor communities
Next steps in gaining CLARITY on CLL
EBMT 2016 presentations overview: GvHD and metabolic syndrome